NTR1011

Phase 1Small molecule

NNeutrolis

NTR1011 is one of 2 small molecule programs targeting SLE (Systemic Lupus). It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

SLE (systemic Lupus)Recruiting

SLE (systemic Lupus)Phase 1

Recruiting

Competition

Competitive Landscape

1 competitor in SLE (systemic Lupus)

#DrugCompanyPhaseTrials

CTX112

CRISPR Therapeutics

Phase 1

1 2

NTR1011

NNeutrolis

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

SLE (systemic Lupus)

NCT07237659

Clinical

Trials by Indication[1]

SLE (Systemic Lupus)1 trial

A Phase 1a/b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety of NTR-1011 in Healthy Adults and Adult Patients With Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)

Recruiting·NNeutrolis·Phase 1·NCT07237659·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NTR1011. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NTR1011 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NTR1011. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Neutrolis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: NNeutrolis

NTR1011

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

SLE (Systemic Lupus)1 trial

References

Drug Info

Quick Facts

Related News